Journal article
When Symptoms Persist: Clozapine Augmentation Strategies
Schizophrenia bulletin, Vol.27(4), pp.615-628
2001
DOI: 10.1093/oxfordjournals.schbul.a006901
PMID: 11824488
Abstract
Recent data and clinical experience confirm that, in spite of superior efficacy for treatment-refractory schizophrenia, a substantial proportion of patients receiving clozapine will continue to experience disabling symptoms. Optimizing clozapine monotherapy is the first step in the management of "clozapine nonresponders." Described here is a synthesis of the available literature on the range and efficacy of clozapine augmentation strategies that may be used when monotherapy fails. Treatment options include adjunctive antipsychotic medications, mood stabilizers, selective serotonin reuptake inhibitors, glycinergic agents, and electroconvulsive therapy. The evidence favoring one augmentation strategy over another is lacking; overall, adjunctive therapy is associated with only modest clinical improvement. Moreover, case series and open-labeled clinical trials dominate the extant literature, and there is a dearth of double-blind trials comparing these augmentation agents. Current systematic efforts to enhance the treatment of these patients with adjunctive therapies are worthy of being studied in carefully conducted clinical trials.
Details
- Title: Subtitle
- When Symptoms Persist: Clozapine Augmentation Strategies
- Creators
- Peter Buckley - Dr. Peter Buckley, Dept. of Psychiatry, Medical College of Georgia, 1515 Pope Avenue, Augusta, GA 30912Alexander MillerJerry OlsenDavid GarverDel D MillerJohn Csernansky
- Resource Type
- Journal article
- Publication Details
- Schizophrenia bulletin, Vol.27(4), pp.615-628
- Publisher
- National Institute of Mental Health
- DOI
- 10.1093/oxfordjournals.schbul.a006901
- PMID
- 11824488
- ISSN
- 0586-7614
- eISSN
- 1745-1701
- Language
- English
- Date published
- 2001
- Academic Unit
- Psychiatry
- Record Identifier
- 9984003416902771
Metrics
22 Record Views